IMO, Merck’s due diligence was time.
Time to see if:
1. Two initial indications were approvable.
2. If the combo had obvious results,
3. If Flaskworks could work and be commercially prepared for equivalence testing.
Now NWBO is showing its value and Merck can see value and remaining potential value. Before, there was no meeting of the minds possible.
Now, because approval is at hand, the combination patent was granted, the combination trial appears to me, watching clinicaltrials.gov behavior, to be a grand slam, and Flaskworks appears ready for prime time equivalence testing, the Iron is Hot!
NWBO may have an ugly PPS, but it has grown into a beautiful Swan for all intents and purposes, and much bigger companies like Novo Nordisk or Lilly could swoop in right now and NWBO might end up a runaway bride.
Merck could be sitting alone wondering what could have been.
Market Data 
Markets 
AI
